E-ISSN 2146-9369 | ISSN 2146-3158
 
2024, Vol: 14, Issue: 4
14 / 4Current Issue ArchiveAims and ScopeAbstracting & IndexingMost Accessed ArticlesMost Downloaded ArticlesMost Cited Articles

Research Article 


Tenofovir therapy in chronic hepatitis B infection: 48-week results from Izmir Province, Turkey

Sukran Kose, Gursel Ersan, Suheyla Serin Senger, Gulsun Akincioglu, Melda Ulusoy, Gulgun Akkoclu.


Cited By:1

Abstract
Objectives: The goal of therapy in chronic hepatitis B infection (CHB) is to impede liver injury by suppressing viral replication. The study was aimed to determine the eficacy of tenofovir (TDF) in CHB infection for 48 weeks.
Materials and methods: We retrospectively analyzed the data of 45 CHB patients treated by tenofovir. The patients were divided into two groups based on their hepatitis B e antigen status (HBeAg). Those who were eligible to therapy received TDF 300 mg once daily for 48 weeks. Serum alanine aminotransferase levels (ALT), hepatitis B virus DNA (HBV DNA), and viral serological markers were checked at three-month intervals. Liver biopsy scores were determined in all patients.
Results: The mean age ± standard deviation (SD) was 35.8 ± 17.0 years, 26 (57.8 %) were male, and seven patients (15.5%) were treatment-experienced by a nucleos(t)ide analogue before TDF. HBeAg was positive in 17 (37.8%) patients. At week 48 among HBeAg positive (HBeAg +) patients ' biochemical and virological response rates at month-3, -6 and -12 were 64.7%, and 100%, 70.6%, and 94.1%, and 88.2%, and 64.7%, respectively. The serological response in HBeAg + patients was 29.4%. For HBeAg negative (HBeAg -) patients; biochemical, and virological response rates were 64.3%, and 96.4% at month 3; 82.1%, and 96.4% at month 6; and 100%, and 85.7% at month 12, respectively. At week 48 both groups had signiicant virological response (p<0.001).
Conclusion: Treatment in CHB with TDF leads to HBV DNA suppression without evident resistance for 48-week, and is well tolerated. J Microbiol Infect Dis 2012; 2(3): 87-92


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Sukran Kose
Articles by Gursel Ersan
Articles by Suheyla Serin Senger
Articles by Gulsun Akincioglu
Articles by Melda Ulusoy
Articles by Gulgun Akkoclu
on Google
on Google Scholar


How to Cite this Article
Pubmed Style

Kose S, Ersan G, Senger SS, Akincioglu G, Ulusoy M, Akkoclu G. Tenofovir therapy in chronic hepatitis B infection: 48-week results from Izmir Province, Turkey. J Microbiol Infect Dis. 2012; 2(3): 87-92 . doi:10.5799/jmid2012.03.0050

Web Style

Kose S, Ersan G, Senger SS, Akincioglu G, Ulusoy M, Akkoclu G. Tenofovir therapy in chronic hepatitis B infection: 48-week results from Izmir Province, Turkey. https://www.jmidonline.org/?mno=302657167 [Access: January 09, 2025]. doi:10.5799/jmid2012.03.0050

AMA (American Medical Association) Style

Kose S, Ersan G, Senger SS, Akincioglu G, Ulusoy M, Akkoclu G. Tenofovir therapy in chronic hepatitis B infection: 48-week results from Izmir Province, Turkey. J Microbiol Infect Dis. 2012; 2(3): 87-92 . doi:10.5799/jmid2012.03.0050


Vancouver/ICMJE Style

Kose S, Ersan G, Senger SS, Akincioglu G, Ulusoy M, Akkoclu G. Tenofovir therapy in chronic hepatitis B infection: 48-week results from Izmir Province, Turkey. J Microbiol Infect Dis. (2012), [cited January 09, 2025]; 2(3): 87-92 . doi:10.5799/jmid2012.03.0050


Harvard Style

Kose, S., Ersan, . G., Senger, . S. S., Akincioglu, . G., Ulusoy, . M. & Akkoclu, . G. (2012) Tenofovir therapy in chronic hepatitis B infection: 48-week results from Izmir Province, Turkey. J Microbiol Infect Dis, 2 (3), 87-92 . doi:10.5799/jmid2012.03.0050


Turabian Style

Kose, Sukran, Gursel Ersan, Suheyla Serin Senger, Gulsun Akincioglu, Melda Ulusoy, and Gulgun Akkoclu. 2012. Tenofovir therapy in chronic hepatitis B infection: 48-week results from Izmir Province, Turkey. Journal of Microbiology and Infectious Diseases, 2 (3), 87-92 . doi:10.5799/jmid2012.03.0050


Chicago Style

Kose, Sukran, Gursel Ersan, Suheyla Serin Senger, Gulsun Akincioglu, Melda Ulusoy, and Gulgun Akkoclu. "Tenofovir therapy in chronic hepatitis B infection: 48-week results from Izmir Province, Turkey." Journal of Microbiology and Infectious Diseases 2 (2012), 87-92 . doi:10.5799/jmid2012.03.0050


MLA (The Modern Language Association) Style

Kose, Sukran, Gursel Ersan, Suheyla Serin Senger, Gulsun Akincioglu, Melda Ulusoy, and Gulgun Akkoclu. "Tenofovir therapy in chronic hepatitis B infection: 48-week results from Izmir Province, Turkey." Journal of Microbiology and Infectious Diseases 2.3 (2012), 87-92 . Print. doi:10.5799/jmid2012.03.0050


APA (American Psychological Association) Style

Kose, S., Ersan, . G., Senger, . S. S., Akincioglu, . G., Ulusoy, . M. & Akkoclu, . G. (2012) Tenofovir therapy in chronic hepatitis B infection: 48-week results from Izmir Province, Turkey. Journal of Microbiology and Infectious Diseases, 2 (3), 87-92 . doi:10.5799/jmid2012.03.0050


Author LoginReviewer LoginAbout PublisherOpen Access PolicyEditorial PoliciesPeer Review PolicyPublication Ethics and Publication Malpractice StatementConflict of Interest PolicyPlagiarism PolicyProtection of Research Participants (Statement On Human And Animal Rights)Privacy PolicyCorrections, Retractions & Expressions of ConcernSelf-Archiving PoliciesDigital Archiving & Preservation PoliciesStatement of Informed ConsentAdvertising PolicyTerms of UseLicense InformationCopyright Information

About Journal of Microbiology and Infectious Diseases

Journal of Microbiology and Infectious Diseases (JMID) is an international "peer review" journal in microbiology, infectious diseases, virology, ... Read more.



For best results, please use Internet Explorer or Google Chrome.

Contact Information

All correspondence should be addressed to:

Prof. Ibrahim Eldaghayes

Editor-in-Chief

Journal of Microbiology and Infectious Diseases

Department of Microbiology and Parasitology 

Faculty of Veterinary Medicine

University of Tripoli

P.O. Box 13662, Tripoli, Libya